Before taking his current role, he spent one year at Amazon Inc.[1] Prior to that he was the Levi Knight chair and professor at the University of California-Los Angeles where he held a multi-departmental professorship in Bioengineering, Radiology, Chemical, and Biomolecular Engineering as well as the Director of Center for Minimally Invasive Therapeutics (C-MIT).
He received his Ph.D. in bioengineering from Massachusetts Institute of Technology under the supervision of Robert S. Langer (2005), and MASc (2001) and BSc (1999) degrees from the University of Toronto both in chemical engineering.
[5] Khademhosseini is a leader in developing ‘personalized’ solutions that utilize micro- and nanoscale technologies to enable a range of therapies for organ failure, cardiovascular disease, and cancer.
His early work in electrochemical biosensors with regeneration ability and microfluidic physical sensors allowed in-line monitoring of organs-on-a-chip platforms.
He combined silica nanoparticles with gelatin to engineer shear-thinning materials for the embolization of blood vessels in the peripheral vasculature.
The technology was approved by U.S. Food and Drug Administration, and Obsidio Medical was acquired by Boston Scientific in August 2022.
[22][23] Omeat is a vertically integrated meat company that also produces humane and cost effective fetal bovine serum replacement.
He is a recipient of the 2011 Presidential Early Career Award for Scientists and Engineers (PECASE) by President Barack Obama, the highest honor given by the US government for early-career investigators.
[33] In 2011, he received the Pioneers of Miniaturization Prize from the Royal Society of Chemistry for his contribution to microscale tissue engineering and microfluidics.